FHTX Q4 2022 Earnings — Foghorn Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

FHTXFoghorn Therapeutics Inc.

$330M

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M+486.8% YoY

Gross Profit

-$24M-574.2% margin

Operating Income

-$32M-762.1% margin

Net Income

-$29M-690.4% margin

EPS (Diluted)

$-0.82

QoQ Revenue Growth

-36.9%

Cash Flow

Operating Cash Flow

-$29M

Free Cash Flow

-$29M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$405M

Total Liabilities

$405M

Stockholders' Equity

$112,000

Cash & Equivalents

$52M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$713,000	+486.8%
Gross Profit	-$24M	-$22M	-10.5%
Operating Income	-$32M	-$28M	-13.5%
Net Income	-$29M	-$29M	+0.9%